Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China

References

• WHO. Consolidated guidelines on tuberculosis: module 4: treatment - drug-resistant tuberculosis treatment [internet]. Geneva: World Health Organization; 2020. PMID: 32603040.
   Google Scholar
• Organization WH. Global tuberculosis report 2014. Geneva: WHO; 2014. Available from: www.who.int/about/licensing/copyright_form/en/index.html.
   Google Scholar
• Organization WH. Global Tuberculosis Report. World Health Organization: Geneva; 2021. Licence: CC BY-NC-SA 30 IGO. 2021.
   Google Scholar
• Pontali E, Raviglione M, Migliori G. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev. 2019;28(152):190035. doi: 10.1183/16000617.0035-2019
   PubMed Web of Science ®Google Scholar
• Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564–74. doi: 10.1183/13993003.00724-2015
   PubMed Web of Science ®Google Scholar
• Vambe D, Kay A, Furin J, et al. Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini. Int J Tuberculosis Lung Dis. 2020;24(10):1095–102. doi: 10.5588/ijtld.20.0082
   PubMed Web of Science ®Google Scholar
• Han X, Chen X, Sha W, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China. Int J Tuberculosis Lung Dis. 2020;24(8):789–94. doi: 10.5588/ijtld.19.0586
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahuja S, Akkerman O, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet (London, England). 2018;392(10150):821–834. doi: 10.1016/S0140-6736(18)31644-1
   PubMed Web of Science ®Google Scholar
• Xia H, Zheng Y, Liu D, et al. Strong increase in moxifloxacin resistance rate among multidrug-resistant mycobacterium tuberculosis isolates in China, 2007 to 2013. Microbiol Spectr. 2021;9(3):e0040921. doi: 10.1128/Spectrum.00409-21
   PubMed Web of Science ®Google Scholar
• Chen X, He G, Lin S, et al. Analysis of serial multidrug-resistant tuberculosis strains causing treatment failure and within-host evolution by whole-genome sequencing. mSphere. 2020;5(6). doi: 10.1128/mSphere.00884-20
   Web of Science ®Google Scholar
• Organization. WH. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.
   Google Scholar
• WHO. WHO Treatment Guidelines For Drug-Resistant Tuberculosis 2016 Updates. Geneva. 2016. Available from: wwwhoint/tb/areas-of-work/drug-resistant-tb/treatment/resources/.
   Google Scholar
• WHO. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Association Ca-T. Chemotherapy guidelines on drug-resistant Tuberculosis(2019). Chin Anti-TB J. 2019;37(5):421–469.
   Google Scholar
• Organization WH. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022. License: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Liu Q, Yang D, Qiu B, et al. Drug resistance gene mutations and treatment outcomes in MDR-TB: a prospective study in Eastern China. PLoS neglected tropical diseases. PLoS negl trop dis. 2021;15(1):e0009068. doi: 10.1371/journal.pntd.0009068
   PubMed Web of Science ®Google Scholar
• Alene K, Yi H, Viney K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis in Hunan Province, China. BMC Infect Dis. 2017;17(1):573. doi: 10.1186/s12879-017-2662-8
   PubMedGoogle Scholar
• Xu C, Pang Y, Li R, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect. 2018;76(4):348–53. doi: 10.1016/j.jinf.2017.12.017
   PubMed Web of Science ®Google Scholar
• Bastos ML, Cosme LB, Fregona G, et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 2017;17(1):718. doi: 10.1186/s12879-017-2810-1
   PubMed Web of Science ®Google Scholar
• Oliveira O, Gaio R, Correia-Neves M, et al. Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000-2016. PLoS One. 2021;16(4):e0250028. doi: 10.1371/journal.pone.0250028
   PubMed Web of Science ®Google Scholar
• Singh N, Singh P, Singh U, et al. Fluroquinolone drug resistance among MDR-TB patients increases the risk of unfavourable interim microbiological treatment outcome: an observational study. J Glob Antimicrob Resist. 2021;24:40–4. doi: 10.1016/j.jgar.2020.11.011
   PubMed Web of Science ®Google Scholar
• Roelens M, Battista Migliori G, Rozanova L, et al. Evidence-based definition for extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2021;204(6):713–22. doi: 10.1164/rccm.202009-3527OC
   PubMed Web of Science ®Google Scholar
• Sabur N, Brar M, Wu L, et al. Low-dose amikacin in the treatment of multidrug-resistant tuberculosis (MDR-TB). BMC infectious diseases. BMC Infect Dis. 2021;21(1):254. doi: 10.1186/s12879-021-05947-6
   PubMed Web of Science ®Google Scholar
• Harausz E, Garcia-Prats A, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15(7):e1002591. doi: 10.1371/journal.pmed.1002591
   PubMed Web of Science ®Google Scholar
• Organization WH. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. License: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2020.
   Google Scholar
• Hwang T, Dotsenko S, Jafarov A, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open. 2014;4(1):e004143. doi: 10.1136/bmjopen-2013-004143
   PubMed Web of Science ®Google Scholar
• Park S, Jo K, Shim T. Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility. Int J Tuberculosis Lung Dis. 2020;24(2):233–9. doi: 10.5588/ijtld.19.0314
   PubMed Web of Science ®Google Scholar
• Kuhlin J, Smith C, Khaemraev A, et al. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan. Int J Tuberculosis Lung Dis. 2018;22(5):544–50. doi: 10.5588/ijtld.17.0483
   PubMed Web of Science ®Google Scholar
• Conradie F, Diacon A, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. doi: 10.1056/NEJMoa1901814
   PubMed Web of Science ®Google Scholar
• Conradie F, Bagdasaryan T, Borisov S, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810–823. doi: 10.1056/NEJMoa2119430
   PubMed Web of Science ®Google Scholar
• Nyang’wa B, Berry C, Kazounis E, et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med. 2022;387(25):2331–43. doi: 10.1056/NEJMoa2117166
   PubMed Web of Science ®Google Scholar
• Tan S, Ding X, Tan Y, et al. The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance. Zhonghua Jie He Hu Xi Za Zhi = Zhonghua Jiehe He Hu Xi Zazhi = Chin J Tubercul Respirat Dis. 2014;37(12):915–918.
   PubMedGoogle Scholar
• Belachew T, Yaheya S, Tilahun N, et al. Multidrug-resistant tuberculosis treatment outcome and associated factors at the university of Gondar comprehensive specialized hospital: a ten-year retrospective study. Infect Drug Resist. 2022;15:2891–9. doi: 10.2147/IDR.S365394
   PubMed Web of Science ®Google Scholar
• Gualano G, Mencarini P, Musso M, et al. Putting in harm to cure: drug-related adverse events do not affect the outcome of patients receiving treatment for multidrug-resistant tuberculosis. Experience from a tertiary hospital in Italy. PLoS One. 2019;14(2):e0212948. doi: 10.1371/journal.pone.0212948
   PubMed Web of Science ®Google Scholar
• Aznar ML, Segura AR, Moreno MM, et al. Treatment outcomes and adverse events from a standardized multidrug-resistant tuberculosis regimen in a rural setting in Angola. Am J Trop Med Hyg. 2019;101(3):502–509. doi: 10.4269/ajtmh.19-0175
   PubMed Web of Science ®Google Scholar